Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018)
Neogenomics' (NEO) quarterly Non-Current Deffered Revenue came in at $1.2 million in Q3 2018, up 85.03% on a QoQ basis from $648000.0 in Q2 2018.
Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Neogenomics (NEO) has 2 years of Non-Current Deffered Revenue data on file, last reported at $1.2 million in Q3 2018.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $1.2 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $1.2 million (changed N/A YoY) and the FY2017 annual result came in at $283000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue improved to $1.2 million in Q3 2018, from $648000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $1.2 million in Q3 2018 to a low of $283000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | - |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | - |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 16.07 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | - |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 32.59 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | - |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | - |
| 10 | Neogenomics | 2.42 Bn | 2.28 Bn | 91.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 1.20 Mn |
| Jun 30, 2018 | 648,000.00 |
| Mar 31, 2018 | 522,000.00 |
| Dec 31, 2017 | 283,000.00 |